<DOC>
	<DOCNO>NCT00357890</DOCNO>
	<brief_summary>Within 4 week diagnosis type 1 diabetes , 10 subject ( pubertal male , 12-17 year old ) randomize either receive multiple daily injection ( MDI ) use Lantus insulin , continuous subcutaneous insulin infusion ( CSII ; pump therapy ) . The propose protocol compare change diabetes control pump therapy MDI treatment group . More importantly , however , study evaluate mode therapy may affect honeymoon period glycemic control , specifically focus change insulin sensitivity ( measure euglycemic-hyperinsulinemic clamp study adiponectin concentration change ) beta cell function ( measure mixed meal tolerance test ) . Demonstrating pump therapy time diagnosis type 1 diabetes prolongs honeymoon phase improve insulin sensitivity beta cell function may important therapeutic implication could influence standard care pediatric diabetes .</brief_summary>
	<brief_title>Insulin Pump Therapy Adolescents With Newly Diagnosed Type 1 Diabetes ( T1D )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Male female patient age 12 17 year inclusive time entry study ( i.e. , 12th 18th birthday ) Type 1 diabetes mellitus 10 day pubertal ( Tanner stage 2 ) The patient parent guardian able simple math calculation ( necessary pump management ) Parent legal guardian must give sign informed consent No chronic medical condition ( wellcontrolled thyroid disease OK , mild asthma OK patient chronic inhale oral daily corticosteroid ) Exceptional psychological stress , expect circumstance new diagnosis diabetes Inability unwillingness comply requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>type 1 diabetes</keyword>
	<keyword>diabetes</keyword>
	<keyword>new onset</keyword>
	<keyword>CSII</keyword>
	<keyword>insulin glargine</keyword>
	<keyword>insulin sensitivity</keyword>
	<keyword>beta cell function</keyword>
	<keyword>beta cell preservation</keyword>
</DOC>